Houston, Texas, United States, November 19, 2026
Johnson & Johnson (J&J) has announced the first commercial installation of its OTTAVA™ Robotic Surgical System at Memorial Hermann-Texas Medical Center in Houston, Texas. The installation marks an important milestone in the commercial launch of the company’s next-generation soft-tissue robotic surgery platform and represents the beginning of its early access commercial programme in the United States. Memorial Hermann will become the first U.S. hospital to use OTTAVA under this programme, building on its longstanding clinical collaboration with Johnson & Johnson. The hospital previously participated in clinical evaluation of the system through the Investigational Device Exemption (IDE) programme that supported its regulatory authorisation. The installation follows the U.S. Food and Drug Administration’s (FDA) De Novo authorisation in July 2026, which cleared the system for use in ten general surgery procedures involving the upper abdomen. The technology has been developed to address operating-room space limitations, surgical workflow complexity and the growing demand for robotic-assisted procedures. Through this commercial milestone, Johnson & Johnson is advancing its strategy to expand robotic surgery capabilities and introduce new technology designed around the needs of surgeons, hospitals and patients.
OTTAVA Introduces a Table-Integrated Robotic Surgery Platform
The OTTAVA Robotic Surgical System is designed around a table-integrated architecture that combines four robotic arms within a standard-sized surgical table. Unlike conventional robotic platforms that use separate robotic equipment positioned around the operating table, OTTAVA integrates its robotic architecture into the surgical table itself. This design aims to help hospitals manage operating-room space more efficiently while supporting surgical teams during complex procedures. The platform incorporates software-controlled automation capabilities, next-generation robotic instrumentation and compatibility with the Polyphonic™ Digital Ecosystem. These technologies are intended to support surgical workflow coordination, procedural efficiency and integration of digital capabilities within the operating environment. Johnson & Johnson designed the system to address practical challenges experienced by hospitals, including limited operating-room space, increasing procedural demands and pressure on healthcare resources. The company also aims to support surgical teams through technology that can adapt to different procedural requirements. The platform’s table-integrated design represents a distinct approach to soft-tissue robotic surgery, although its real-world clinical and operational benefits will continue to be evaluated as more hospitals begin using the system.
FDA De Novo Authorisation Covers Ten General Surgery Procedures
In July 2026, the FDA granted De Novo marketing authorisation for OTTAVA, establishing a new regulatory classification for the table-integrated soft-tissue robotic surgical system. The authorisation covers ten upper-abdominal general surgery procedures, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair. This regulatory milestone enabled Johnson & Johnson to begin its U.S. commercial launch with selected customers. The company is also continuing clinical evaluation of the platform in additional surgical applications. Its collaboration with Memorial Hermann includes experience from the clinical evaluation programme, particularly the use of OTTAVA in Roux-en-Y gastric bypass procedures. The hospital’s involvement in the earlier clinical programme provides continuity as the system moves from clinical evaluation into commercial use. Johnson & Johnson plans to work with selected hospitals and surgical teams during the early launch phase while collecting additional clinical data and real-world evidence. The company also intends to evaluate the platform for further indications and regulatory markets over time. The existing FDA authorisation should not be interpreted as clearance for every type of robotic surgery or all surgical procedures.
Memorial Hermann Partnership Advances Robotic Surgery Adoption
The installation reflects a collaborative relationship between Johnson & Johnson MedTech and Memorial Hermann Health System, with both organisations working to advance surgical technology through clinical experience and hospital-based implementation. Memorial Hermann-Texas Medical Center served as a clinical trial site for OTTAVA, while surgeons involved in the programme contributed experience during the system’s development and evaluation. Erik Wilson, MD, Chief of Minimally Invasive and Elective General Surgery at UTHealth Houston and Director of Bariatric Surgery at Memorial Hermann-Texas Medical Center, served as the lead investigator for the FORTE clinical study. He highlighted the importance of bringing new surgical technologies into clinical practice and the value of collaboration between clinicians and technology developers. Johnson & Johnson plans to continue the commercial rollout with selected U.S. customers, focusing on early customer experience while generating further clinical evidence. The installation represents a step forward in the company’s surgical robotics strategy and expands the range of technologies available for hospitals exploring robotic-assisted surgery. As adoption progresses, clinical experience and real-world evidence will be important in assessing the platform’s performance, workflow impact and potential benefits for surgical teams and patients.
Source: Johnson & Johnson press release



